Marketing that a medical reviewer would sign

Healthcare advertising in Singapore and Malaysia is tightly limited: patient testimonials, superlatives and comparative claims are restricted, many Malaysian healthcare advertisements need approval before publication, and doctors work under professional rules on promotion. I run a review process in which every clinical statement on our channels passes the medical review panel before release, and the compliance reviewer in my team checks the wording against each market's rules. I ask a plain question of every draft: could the doctor named or implied here defend this sentence to a colleague? When the answer is uncertain, we describe the service rather than its result. The review adds about four working days to a campaign, and I plan launches around it rather than ask for exceptions. That costs us some persuasive copy. It also means our hospital chief executives have not had to withdraw a published advertisement since 2019.

Many Indonesian patients still arrive with help from an independent facilitator who arranges interpretation, travel and accommodation. Those services are valuable, and I want them paid for. What I will not accept is payment linked to the final hospital bill, which gives the facilitator an interest in a larger procedure. Since 2022 we accredit facilitators against published criteria, pay fixed annual fees for defined services and audit a sample of patient journeys each quarter. A facilitator who fails an audit receives a written finding and one chance to correct it before accreditation is withdrawn. Our own offices in Medan and Pekanbaru give patients a route that involves no intermediary at all. I also track complaints about facilitators separately, because they are often the first sign that a payment arrangement is shaping advice it should not touch.

Health screening is sold to healthy people, which makes overselling easy and its consequences hard to see. I write package descriptions with our screening doctors so that each test is explained alongside what it cannot tell a person and what a borderline result may lead to. Add-on tests are suggested through a pre-visit health questionnaire reviewed by a nurse or doctor against guidance the medical team owns, not at the registration counter. Every new package is approved by the screening medical lead before it is priced. Staff are rewarded for service quality rather than add-on sales. For corporate clients we report participation and follow-up rates, never the volume of tests sold. The commercial result is lower revenue per visit and steadier employer contracts, which I consider a better business for a screening provider.

Patients read public reviews before choosing a hospital, especially when they are travelling. We do not pay for reviews, offer incentives for them or ask staff to write them. My team responds to every public review within three working days, without confirming that the writer was a patient or mentioning any treatment, and passes each complaint to the hospital's patient-relations team. Instead of testimonials, we publish patient-experience survey results twice a year, with the number of responses, the response rate and the questions on which we scored worst. The quality team, not marketing, sets the questions and the sampling, so I cannot choose which results appear. Publishing weak scores was uncomfortable at first. It has made the survey more useful internally, because hospital managers know their results will be seen.

A patient flying from Medan needs to know roughly what a procedure will cost before deciding to come. A single starting price misleads; a full estimate is impossible before a consultation. We publish typical bill ranges drawn from the previous year's actual invoices, stating what is excluded and how often bills exceeded the upper figure. After consultation, the patient receives a written estimate approved by the hospital's billing office. I report to the board how often final bills fall outside that estimate, by procedure group; in 2025 it was twelve per cent of international admissions, and billing reviews each case with my team monthly. Where variation is too wide to publish honestly, as with some complex cardiac care, we withdraw the range and say why rather than keep a misleading figure online.